A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Trial Profile

A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Pegfilgrastim; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 08 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Dec 2015 Results from part 1 (n = 15) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 20 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top